Breaking News, Collaborations & Alliances

BioNTech, DualityBio Partner to Develop Differentiated ADCs for Solid Tumors

Collaboration will add a new class of precision medicine therapeutics to BioNTech’s clinical-stage oncology portfolio.

BioNTech SE and Duality Biologics (Suzhou) Co. Ltd., a clinical-stage biotech company developing next generation antibody-drug conjugate (ADC) therapeutics to treat cancer and autoimmune diseases, entered into exclusive license and collaboration agreements for two ADC assets to develop, manufacture and commercialize the two assets globally, excluding Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region. ADCs will become an additional drug class in Bi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters